scholarly journals What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine

2021 ◽  
Author(s):  
Adrian S. Wagg ◽  
Sender Herschorn ◽  
Martin Carlsson ◽  
Mireille Fernet ◽  
Matthias Oelke
Keyword(s):  
Overactive Bladder ◽  
Adverse Events ◽  
Responder Analysis

PD36-02 MIRABEGRON ADD-ON TREATMENT TO SOLIFENACIN IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS: A RESPONDER ANALYSIS OF A RANDOMIZED, DOUBLE BLIND, PHASE 3B STUDY

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Scott MacDiarmid ◽  
Salman Al-Shukri ◽  
Jack Barkin ◽  
Aino Fianu-Jonasson ◽  
Philippe Grise ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Double Blind ◽  
Responder Analysis

Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder

Urology ◽  
2020 ◽  
Vol 135 ◽  
pp. 32-37 ◽  
Author(s):  
Mohammad Abrar ◽  
Luke Stroman ◽  
Sachin Malde ◽  
Eskinder Solomon ◽  
Arun Sahai
Keyword(s):  
Botulinum Toxin ◽  
Overactive Bladder ◽  
Adverse Events ◽  
Botulinum Toxin A ◽  
Poor Response ◽  
Toxin A

Trospium chloride for overactive bladder may induce central nervous system adverse events

2014 ◽  
Vol 5 (3) ◽  
pp. 220-224 ◽  
Author(s):  
S. Liabeuf ◽  
V. Gras ◽  
J. Moragny ◽  
C. Durand-Maugard ◽  
K. Masmoudi ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Overactive Bladder ◽  
Adverse Events ◽  
Trospium Chloride

Efficacy and Adverse Events of Antimuscarinics for Treating Overactive Bladder: Network Meta-analyses

2012 ◽  
Vol 62 (6) ◽  
pp. 1040-1060 ◽  
Author(s):  
Nora Buser ◽  
Sandra Ivic ◽  
Thomas M. Kessler ◽  
Alfons G.H. Kessels ◽  
Lucas M. Bachmann
Keyword(s):  
Overactive Bladder ◽  
Adverse Events ◽  
Meta Analyses

scholarly journals Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Raúl Vozmediano-Chicharro ◽  
Blanca Madurga ◽  
Pedro Blasco
Keyword(s):  
Overactive Bladder ◽  
Adverse Events ◽  
Application Site ◽  
Overactive Bladder Syndrome ◽  
Good Tolerability ◽  
Subgroup Analyses ◽  
Voiding Diary ◽  
Previously Treated ◽  
Clinical Records

Objectives. Evaluation of changes in symptoms among patients with overactive bladder syndrome treated with transdermal oxybutynin and tolerability after 12 months of follow-up. Methods. This was a multicenter, retrospective, single-cohort, observational study. Changes in symptoms were evaluated primarily with a 3-day voiding diary. Results were compared to baseline. Subgroup analyses were performed in patients previously treated for OAB or not and aged < 65 years versus ≥65 years. Results. Clinical records of 105 patients were examined; 92.4% were women. At 12 months, 58 patients continued to receive transdermal oxybutynin. Changes in symptoms according to the voiding diary were evaluated in 47 patients. Significant improvements from baseline were observed in urinary frequency (−2.6 voids/24 hours (95% CI: −3.5; −1.8), p<0.001); daily number of urgent episodes (−4.7 episodes/day (95% CI: −6.1; −3.6), p<0.001); and urge incontinence (−1.9 episodes/day (95% CI: −2.9; −1.3), p<0.001). No statistically significant differences were found in subgroup analyses. In total, 38.1% of patients had adverse events, primarily in the application site (27.6%). No severe systemic adverse events occurred. Only 6 patients (5.7%) reported dry mouth. Conclusions. Improved symptoms and good tolerability observed after 1 year of treatment with transdermal oxybutynin shows that it currently has a place in the treatment of OAB patients.

Sign in / Sign up

Export Citation Format

Share Document